Table 1.

Baseline characteristics of patients in the 3 treatment groups [N = 112]

	Standard of care group [Controls]	Ivermectin1 2 mg group [Iv12]	Ivermectin 24 mg group [Iv24]
Total number	39	38	35
Median age [years]; range	43.2 [3–77]	38.5 [6–70]	42.3 [4–73]
Children < 15 years	2 [5.2%]	3 [7.9%]	4 [11.4%]
Gender—Male:Female	30:9	30:8	19:16
Type of disease
Malignant	30 [73.2%]	29 [72.5%]	26 [66.7%]
Acute leukemia	11	13	10
Chronic leukemia	2	2	2
Lymphoma	9	9	14
Myeloma	8	1	3
MPN	–	1	–
Non-malignant	9 [21.9%]	9 [22.5%]	9 [23.1%]
Aplastic anemia	2	4	6
Megaloblastic anemia	–	1	1
ITP/AIHA/PRCA	3	3	1
Sickle cell disease	1	1	–
Bleeding disorders#	2	–	1
Disease activity
Remission	17 [41.5%]	14 [36.8%]	13 [33.3%]
Active on treatment	13 [36.6%]	18 [47.3%]	14 [46.2%]
Relapsed/refractory	9 [21.9%]	6 [15.9%]	8 [20.5%]
Previous transplant [allo/auto]	3 [1/2]	6 [3/3]	2 [2/0]
Platelet count < 50 × 109/L	12 [29.2%]	19 [50%]	19 [54.2%]
ANC < 1 × 109/L	13 [31.7%]	16 [42.1%]	18 [51.4%]
Neutrophil–lymphocyte ratio [NLR]
Normal [1–3]	14 [39.1%]	11 [28.9%]	11 [31.6%]
High [> 3]	16 [39.1%]	18 [47.4%]	12 [34.2%]
Low [< 1]	9 [21.9%]	9 [23.7%]	12 [34.2%]
Increased D-dimer [n = 104]	26 [68.2%]	27 [71.1%]	24 [68.5%]
Increased CRP [n = 96]	28 [68.2%]	25 [65.7%]	26 [74.2%]
Increased Ferritin [n = 105]	26 [63.4%]	32 [84.2%]	27 [77.1%]
COVID infection status
Asymptomatic	6 [14.6%]	4 [10.5%]	4 [11.5%]
Mild	20 [53.7%]	26 [68.4%]	21 [60%]
Moderate	13 [31.7%]	8 [21.1%]	10 [28.5%]

MPN, Myeloproliferative disorders; ITP, Immune thrombocytopenia; AIHA, Autoimmune hemolytic anemia; PRCA, Pure red cell aplasia; DM, Diabetes Mellitus; HT, Hypertension; IHD, Ischaemic heart disease; Allo, Allogeneic transplant; Auto, Autologous transplant; ANC, Absolute neutrophil count

^#Consisted of severe hemophilia [1] and Afibrinogenemia [2]